This script search US Code. View Rule
Menu Item - Home
Menu Item - Agenda Main page
Menu Item - Historical Agenda
Menu Item - Historical Agenda
Menu Item - Agenda Search
Menu Item - EO Dashboard
Menu Item - Reg Review
Menu Item - EO Agency lists
Menu Item - EO Search
Menu Item - EO Historical Reports
Menu Item - Review Counts
Menu Item - OIRA Letters
Menu Item - EOM 12866 Search
Menu Item - EO XML Reports
Menu Item - ICR Dashboard page
Menu Item - ICR Main page
Menu Item - ICR Search
Menu Item - ICR XML Reports
Menu Item - FAQ
Menu Item - Additional Resources
Menu Item - Contact Us
Search: Agenda Reg Review ICR
       Search

View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML

HHS/FDA RIN: 0910-AF46 Publication ID: Fall 2004 
Title: ●Substances Prohibited From Use in Animal Food or Feed 
Abstract: The Food and Drug Administration (FDA) is proposing to amend its regulations to prohibit the use of certain cattle origin materials in the food or feed of all animals to help strengthen existing safeguards to prevent the spread of bovine spongiform encephalopathy (BSE) in U.S. cattle. The discovery of a BSE-positive dairy cow in December 2003 has caused FDA to review its policies for prevention of BSE which resulted in this rulemaking. 
Agency: Department of Health and Human Services(HHS)  Priority: Economically Significant 
RIN Status: First time published in the Unified Agenda Agenda Stage of Rulemaking: Proposed Rule Stage 
Major: Yes  Unfunded Mandates: No 
CFR Citation: 21 CFR 589.2001 
Legal Authority: 21 USC 321; 21 USC 342; 21 USC 343; 21 USC 349; 21 USC 371 
Legal Deadline:  None

Statement of Need: In December 2003, the U.S. Department of Agriculture (USDA) announced a positive case of BSE in a dairy cow in Washington State. Subsequent epidemiological investigations confirmed that the infected cow was born and most likely became infected in Alberta, Canada, prior to Canada's 1997 implementation of a ban on feeding mammalian protein to ruminants. This case followed the identification of BSE in a single cow in Alberta, Canada, in May 2003. In response to the identification of these BSE cases in North America, FDA is proposing to amend its regulations to prohibit the use of certain cattle origin materials in the food or feed of all animals. This measure will further strengthen existing safeguards designed to help prevent the spread of BSE in U.S. cattle. BSE belongs to a family of diseases known as transmissible spongiform encephalopathies (TSEs). TSE’s are fatal, progressively degenerative central nervous system diseases of man and other animals. TSE’s include, among other diseases, BSE in cattle, scrapie in sheep and goats, chronic wasting disease (CWD) in deer and elk, and Creutzfeldt-Jakob disease (CJD) in humans. There is no known treatment for these diseases, and there is no vaccine to prevent them. In addition, although validated postmortem diagnostic tests are available, there are no validated diagnostic tests for BSE that can be used to test for the disease in live animals. In the Federal Register of July 14, 2004 (69 FR 42288), FDA and USDA jointly published an advance notice of proposed rulemaking (ANPRM) to inform the public about the recommendations made by a team of international BSE experts (IRT) convened by the Secretary of Agriculture in January 2004 and to request comments on a number of issues related to possible regulatory measures. Among other recommendations, the IRT recommended that: 1) all specified risk materials (SRMs) be excluded from all animal feed including pet food; 2) cross contamination be prevented throughout thfeed chain; and 3) the use of all mammalian and poultry protein in ruminant feed be prohibited. FDA intends to consider all information received in response to the ANPRM prior to making a determination as to what measures are needed to further strengthen animal feed safeguards.

Summary of the Legal Basis: The agency is proposing these regulations under sections 402 and 701 of the Federal Food, Drug, and Cosmetics Act.

Alternatives: FDA has considered four other measures that are not included in the proposed rule. These measures include: 1) a requirement that those facilities handling both prohibited materials and ruminant feeds use dedicated facilities or equipment for each; 2) a ban on the use of poultry litter in ruminant feeds; 3) a ban on the use of blood and blood products in ruminant feeds; and 4) a ban on the use of what is commonly referred to as plate waste in ruminant feeds.

Anticipated Costs and Benefits: The proposed regulation may be expected to require the expenditure of over $100 million in any one year by the private sector and may have a significant impact on a substantial number of small entities. The estimated total annualized costs of the rule are the sum of the costs of prohibiting the list of cattle origin materials identified in the proposed rule. The benefit of the proposed rule includes the elimination of much of the remaining risk of spreading BSE in U.S. cattle. Assuming the hypothetical import of five infected cattle, FDA believes that the proposed rule would effectively remove about 95 percent of the remaining risk of human exposure to BSE infected material. The U.S. economy may also benefit from increased exports to the extent that the rule persuades foreign governments to import U.S. beef products. While we are unable to quantify these benefits, they are potentially large, given the significant loss of exports resulting from the discovery of an infected cow in Washington State.

Risks: BSE is an incurable disease that can affect cattle and certain other mammals that ingest infective material from BSE infected cattle. In 1996, a newly recognized form of the human disease, Creutzfeldt-Jakob disease (CJD), referred to as variant CJD (vCJD), was reported in the United Kingdom. Scientific and epidemiological studies have linked vCJD to exposure to the BSE agent, most likely through human consumption of beef products contaminated with the agent that causes BSE. The discovery of a BSE positive dairy cow in Washington State in December 2003, caused the Agency to review its policies for the prevention of the spread of BSE within the United States. The need for regulatory action in this case is related to the inability of the market and existing regulations to ensure that the risk of BSE exposure through animal feed is minimized to the extent possible, given that BSE could potentially have an enormous adverse impact on both animal and human health.

Timetable:
Action Date FR Cite
ANPRM  07/14/2004  69 FR 42288 
ANPRM Comment Period End  08/13/2004   
NPRM  02/00/2005   
Regulatory Flexibility Analysis Required: Yes  Government Levels Affected: None 
Small Entities Affected: Businesses  Federalism: No 
Included in the Regulatory Plan: Yes 
Agency Contact:
Burt Pritchett
Biologist
Department of Health and Human Services
Food and Drug Administration
Center for Veterinary Medicine, Room 2654 (MPN-4, HFV-222), 7519 Standish Place,
Rockville, MD 20855
Phone:240 453-6860
Fax:240 453-6882
Email: burt.pritchett@fda.hhs.gov

 
About Us   Vertical Spacer Spacer Related Resources   Vertical Spacer Spacer Disclosure   Vertical Spacer Spacer Accessibility   Vertical Spacer Spacer Privacy Policy   Vertical Spacer Spacer Contact Us